ALMS — ALUMIS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847367 ·
Last close
$4.84
Market Cap
$628.33M
52W High
$31.35
52W Low
$4.70
ADV30
1,913,621
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,907,000 | — | -99,076,000 | -94,881,000 | 488,711,000 | 57,691,000 | 110,286,000 |
| Jun 2026 | 1,662,000 | — | -107,031,000 | -142,221,000 | 560,618,000 | 63,706,000 | 108,460,000 |
| Mar 2026 | 1,741,000 | — | -98,409,000 | -93,053,000 | 671,588,000 | 63,885,000 | 104,567,000 |
| Dec 2025 | 1,929,000 | — | -96,445,000 | -92,931,000 | 411,940,000 | 89,670,000 | 110,643,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-351,398,000
Investing CF
$-97,944,000
Financing CF
$360,934,000
CapEx
$-1,054,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,137,150,000
Inventory
—
Receivables
$3,860,000
ST Investments
$438,587,000
EBIT TTM
$-417,177,000
Pretax Income TTM
$-440,714,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,239,000
EBITDA
$-426,366,016
Free Cash Flow
$-212,242,128
Enterprise Value
$330,965,440
Total Cash
$431,337,984
Total Debt
$35,306,000
Shares Out
129,820,970
Trailing EPS
$-3.53
Book Value
$2.92
ROE
-110.9%
ROA
-55.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 24,050,000 | -453,804,000 | -243,325,000 | 411,940,000 | 110,643,000 | 301,297,000 | -369,523,000 |
| Dec 2024 | 0 | -300,754,000 | -294,233,000 | 340,992,000 | 80,888,000 | 260,104,000 | -255,078,000 |
| Dec 2023 | 0 | -158,174,000 | -154,993,000 | 89,612,000 | 428,872,000 | -339,260,000 | -129,975,000 |
| Dec 2022 | 0 | -113,850,000 | -111,930,000 | 108,168,000 | 303,410,000 | -195,242,000 | -107,722,000 |
TTM Snapshot
Revenues TTM
$7,398,000
NetIncome TTM
$-438,957,000
OpCashFlow TTM
—
Assets (Latest)
$560,618,000
Forward EPS
$-2.95
Max Pain — expiry 2027-01-15
max pain strike: $7.00 · spot: $4.39 · call oi: 10,355 · put oi: 23,280
Expected Move to 2027-01-15:
±$3.15
(71.67%) —
implied range
$1.25 –
$7.54
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | $630.12M | $9.84 | — |
| OLMA | Olema Oncology, Inc. | $632.52M | $7.22 | — |
| ABUS | Arbutus Biopharma Corp | $620.84M | $4.05 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
News headlines (Yahoo Finance, 1h cache)
Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUS
2026-11-16 09:08 · Yahoo
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
2026-11-12 21:05 · Yahoo
Alumis (ALMS) Faces Pressure After Clinical Results
2026-11-12 17:27 · Yahoo
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
2026-10-09 17:11 · Yahoo
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
2026-10-09 08:00 · Yahoo
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
2026-09-09 01:30 · Yahoo
Alumis to Participate in Upcoming September Investor Conferences
2026-09-04 12:00 · Yahoo
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
2026-09-03 14:10 · Yahoo
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
2026-09-03 12:15 · Yahoo
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
2026-09-03 11:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.